Overexpression of prohibitin-1 inhibits RANKL-induced activation of p38-Elk-1-SRE signaling axis blocking MKK6 activity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2015-08-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbrc.2015.06.053PMID 26079882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of SRE and AP1 by olfactory receptors via the MAPK and Rho dependent pathways.

  2013cited by this paper
• Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases.

  2013cited by this paper
• Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway.

  2012cited by this paper
• Gene expression profiles of prohibitin in testes of Octopus tankahkeei (ot-phb) revealing its possible role during spermiogenesis

  2012cited by this paper
• Mitochondrial Dysfunction and Adipogenic Reduction by Prohibitin Silencing in 3T3-L1 Cells

  2012cited by this paper
• Prohibitin has an important role in adipocyte differentiation

  2012cited by this paper
• VapB as a regulator of osteoclastogenesis via modulation of PLCγ2‐Ca2+‐NFAT signaling

  2012cited by this paper
• Chemical affinity matrix-based identification of prohibitin as a binding protein to anti-resorptive sulfonyl amidine compounds.

  2011cited by this paper
• The role and therapeutic potential of prohibitin in disease.

  2011cited by this paper
• Therapeutic targeting of osteoclast function and pathways

  2011cited by this paper
• The p38 SAPK Is Recruited to Chromatin via Its Interaction with Transcription Factors*

  2010cited by this paper
• The role of prohibitin in cell signaling

  2010cited by this paper
• Prohibitin: a potential biomarker for tissue-based detection of gastric cancer

  2008cited by this paper
• Mitogen-induced recruitment of ERK and MSK to SRE promoter complexes by ternary complex factor Elk-1

  2008cited by this paper
• Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway

  2008cited by this paper
• The molecular understanding of osteoclast differentiation.

  2007cited by this paper
• The Prohibitins: emerging roles in diverse functions

  2006cited by this paper
• Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.

  2006cited by this paper
• NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation.

  2006cited by this paper
• The Journal of Experimental Medicine CORRESPONDENCE Hiroshi Takayanagi:

  2005cited by this paper
• Loss of Net as Repressor Leads to Constitutive Increased c-fos Transcription in Cervical Cancer Cells*

  2005cited by this paper
• Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1*

  2004cited by this paper
• Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos*

  2004cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

  2003cited by this paper
• Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator*

  2002cited by this paper
• Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

  2002cited by this paper
• Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter

  2002cited by this paper
• p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function.

  2002cited by this paper
• JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms

  2002cited by this paper
• Tumor Necrosis Factor- (cid:1) Supports the Survival of Osteoclasts through the Activation of Akt and ERK*

  2001cited by this paper
• Characterization of prohibitin in a newly established rat ovarian granulosa cell line.

  2001cited by this paper
• Therapeutic approaches to bone diseases.

  2000cited by this paper
• Bone resorption by osteoclasts.

  2000cited by this paper
• Immunolocalization and expression of prohibitin, a mitochondrial associated protein within the rat ovaries

  1999cited by this paper
• E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition.

  1999cited by this paper
• MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway

  1996cited by this paper
• c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.

  1994cited by this paper

• Prohibitin modulates periodontium differentiation in mice development

  2024cites this paper
• The prohibitin-binding compound fluorizoline induces the pro-inflammatory cytokines interleukin-8 and interleukin-6 through the activation of JNK and p38 MAP kinases.

  2023cites this paper
• Role of Prohibitins in Aging and Therapeutic Potential Against Age-Related Diseases

  2021influential citation
• Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases

  2020cites this paper
• Development of prohibitin ligands against osteoporosis.

  2020cites this paper
• Effects of macrophages and CXCR2 on adipogenic differentiation of bone marrow mesenchymal stem cells

  2018cites this paper